Evidence map›Paper›PMID 31582541›Full record

ArticleHaematologica2020

A high-content cytokine screen identifies myostatin propeptide as a positive regulator of primitive chronic myeloid leukemia cells.

Sofia von Palffy, Niklas Landberg, Carl Sandén, Dimitra Zacharaki, Mansi Shah, Naoto Nakamichi, Nils Hansen, Maria Askmyr, Henrik Lilljebjörn, Marianne Rissler and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Eomesodermin in CD4International journal of biological sciences · 2021
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 3 countries.

Sofia von PalffyDivision of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden sofia.von_palffy@med.lu.se.
Niklas LandbergDivision of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.
Carl SandénDivision of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.
Dimitra ZacharakiDivision of Molecular Hematology, Lund Stem Cell Center, Lund University, Lund, Sweden.
Mansi ShahDivision of Hematology, Oncology and Bone Marrow Transplantation, University of Alabama at Birmingham, Birmingham, AL, USA.
Naoto NakamichiTerry Fox Laboratory, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
Nils HansenDivision of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.
Maria AskmyrDivision of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.
Henrik LilljebjörnDivision of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.
Marianne RisslerDivision of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.
Christine KarlssonDivision of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.
Stefan SchedingDivision of Molecular Hematology, Lund Stem Cell Center, Lund University, Lund, Sweden.
Johan RichterDepartment of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden.
Connie J EavesTerry Fox Laboratory, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
Ravi BhatiaDivision of Hematology, Oncology and Bone Marrow Transplantation, University of Alabama at Birmingham, Birmingham, AL, USA.
Marcus JäråsDivision of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.
Thoas FioretosDivision of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden thoas.fioretos@med.lu.se.
Lund University · SEBC Cancer Agency · CASkåne University Hospital · SEUniversity of Alabama at Birmingham · US

Funding

Microenvironmental Regulation of Leukemia Stem CellsR01CA172447 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BHATIA, RAVI · 2013 to 2023
$3.4M
Leukemia stem cell regulation and resistanceR01CA248794 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BHATIA, RAVI · 2021 to 2025
$2.1M
NCI NIH HHS R01 CA172447NCI NIH HHS R01 CA248794
6 · The paper itself

Abstract

Aberrantly expressed cytokines in the bone marrow (BM) niche are increasingly recognized as critical mediators of survival and expansion of leukemic stem cells. To identify regulators of primitive chronic myeloid leukemia (CML) cells, we performed a high-content cytokine screen using primary CD34

Indexed as

Hematopoietic Stem CellsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveAntigens, CD34Bone MarrowCells, CulturedCytokinesHumansMyostatinAntigens, CD34CytokinesMyostatin

Identifiers

PMID31582541
PMCPMC7395258
OpenAlexW2978446598

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.